Literature DB >> 27330767

Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report.

Yoko Yamamoto1, Ken Kodama1, Tomohiro Maniwa1, Masashi Takeda2, Hiroki Kishima3.   

Abstract

It is widely known that echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement mostly occurs in the adenocarcinoma subtype of non-small-cell lung cancer (NSCLC). Patients with squamous cell carcinoma harboring the ALK rearrangement are extremely rare. This is a case report of a squamous cell carcinoma patient with EML4-ALK rearrangement. An elderly man with a heavy smoking history presented with a mass lesion in the right main bronchus. Bronchoscopic biopsy of the tumor confirmed a diagnosis of squamous cell carcinoma, and it was proven to harbor ALK rearrangement, based on fluorescence in situ hybridization, but not epidermal growth factor receptor mutations. The patient underwent radiation therapy, with a markedly favorable response. ALK-targeted treatment may be a viable option if disease progression occurs in such a case in the future.

Entities:  

Keywords:  anaplastic lymphoma kinase; lung cancer; squamous cell carcinoma

Year:  2016        PMID: 27330767      PMCID: PMC4907124          DOI: 10.3892/mco.2016.878

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  6 in total

1.  A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.

Authors:  Akihiro Tamiya; Shigeki Shimizu; Shinji Atagi
Journal:  J Thorac Oncol       Date:  2015-08       Impact factor: 15.609

2.  ALK-rearranged squamous cell lung cancer: a case report.

Authors:  Quan Zhang; Jinghui Wang; Shucai Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 4.  Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.

Authors:  Cristina Teixidó; Niki Karachaliou; Vicente Peg; Ana Gimenez-Capitan; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2014-04

5.  ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.

Authors:  Anna Caliò; Alessia Nottegar; Eliana Gilioli; Emilio Bria; Sara Pilotto; Umberto Peretti; Stefania Kinspergher; Francesca Simionato; Serena Pedron; Sakari Knuutila; Giampaolo Tortora; Albino Eccher; Antonio Santo; Luca Tondulli; Giorgio Inghirami; Fabrizio Tabbò; Guido Martignoni; Marco Chilosi; Aldo Scarpa; Matteo Brunelli
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

6.  Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.

Authors:  Qiushi Wang; Yong He; Xin Yang; Yubo Wang; Hualiang Xiao
Journal:  BMC Pulm Med       Date:  2014-05-15       Impact factor: 3.317

  6 in total
  3 in total

Review 1.  ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.

Authors:  Nobuaki Mamesaya; Kazuhisa Nakashima; Tateaki Naito; Takashi Nakajima; Masahiro Endo; Toshiaki Takahashi
Journal:  BMC Cancer       Date:  2017-07-06       Impact factor: 4.430

2.  Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Authors:  Junko Watanabe; Shinsaku Togo; Issei Sumiyoshi; Yukiko Namba; Kentaro Suina; Takafumi Mizuno; Kotaro Kadoya; Hiroaki Motomura; Moe Iwai; Tetsutaro Nagaoka; Shinichi Sasaki; Takuo Hayashi; Toshimasa Uekusa; Kanae Abe; Yasuo Urata; Fuminori Sakurai; Hiroyuki Mizuguchi; Shunsuke Kato; Kazuhisa Takahashi
Journal:  Oncotarget       Date:  2018-05-08

3.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Qiyi Meng; Yujie Dong; Hong Tao; Liang Shi; Li Tong; Junfang Tang; Shucai Zhang; Zhe Liu
Journal:  Thorac Cancer       Date:  2021-02-09       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.